ALK and non-small cell lung carcinoma: Although the proportion of concurrent EGFR/ALK co-mutation in NSCLC was rare, some cases or studies reported the occurrence of this situation (7–12), underscoring the necessity for accurate biomarker testing to identify subgroups of NSCLC with oncogenic drivers before treatment.